Emavusertib (CA-4948)

Lymphoma

Leukemia

Other Solid Tumors

Filters:

June 2024

TakeAim Lymphoma Clinical Outcomes ASCO 2024 Poster

December 2023

TakeAim Lymphoma Clinical Outcomes ASH 2023 Poster

December 2023

TakeAim Lymphoma PCNSL Clinical Outcomes ASH 2023 TiP Poster

October 2023

Preclinical Emavusertib + BTKi Synergy AACR-NCI-EORTC Poster 2023

September 2023

IRAK4 Symposium 2023 Highlights

July 2023

Emavusertib in Leukemia and Lymphoma DAVA Oncology Summit on Heme Malignancies 2023

November 2022

TakeAim Lymphoma PCNSL Ibrutinib Combination Therapy Clinical Outcomes SNO 2022 Poster

October 2022

IRAK4 Symposium 2022 Highlights

August 2022

TakeAim Lymphoma Monotherapy Clinical Outcomes PCNSL SNO 2022 Oral Presentation

June 2022

TakeAim Lymphoma Clinical Outcomes EHA 2022 Poster

June 2022

TakeAim Lymphoma PCNSL Ibrutinib Combination Therapy Clinical and Preclinical Data Investor Presentation June 2022

June 2022

TakeAim Lymphoma Clinical Outcomes ASCO 2022 Poster

April 2021

Preclinical Emavusertib in PI3K/BTKi Resistant Marginal Zone Lymphoma Models AACR 2021 Oral Presentation

April 2021

Preclinical Emavusertib in PCNSL Models AACR 2021 Oral Presentation

March 2021

NF-κB Phospho-p50 as a Predictive Biomarker for Emavusertib in NHL AACR 2021 Poster

December 2020

Emavusertib KOL Event ASH 2020

December 2020

TakeAim Lymphoma Clinical Outcomes ASH 2020 Oral Presentation

December 2020

TakeAim Lymphoma Ibrutinib Combination ASH 2020 TiP Poster

September 2019

TakeAim Lymphoma SOHO 2019 TiP Poster

April 2019

Emavusertib Development and PK WRRS 2019 Oral Presentation

December 2018

TakeAim Lymphoma Preliminary Results and Preclinical Data ASH 2018 Poster

October 2018

Preclinical Emavusertib in NHL IWWM 2018 Poster

April 2018

Preclinical Emavusertib in Mantle Cell Lymphoma AACR 2018 Poster

December 2017

Preclinical Emavusertib + Venetoclax in an ABC-DLBCL Xenograft Model ASH 2017 Poster

April 2017

Preclinical Emavusertib in DLBCL Xenograft Models AACR 2017 Poster

May 2016

Preclinical Emavusertib Activity, PD/PK, and Toxicity (Aurigene IRAK4) AACR 2016 Poster

November 2015

Preclinical Activity of IRAK4 Inhibitors ABC-DLBCL Xenograft Models AACR-NCI-EORTC 2015

May 2015

Preclinical Activity of IRAK4 Inhibitors in MYD88 L265P DLBCL Cell Lines AACR 2015 Poster

Filters:

June 2024

TakeAim Leukemia FLT3 Clinical Outcomes EHA 2024 Poster

June 2024

TakeAim Leukemia Clinical Outcomes ASCO 2024 Poster

June 2024

TakeAim Leukemia Emavusertib as Add-On to Venetoclax and Azacitidine in MRD+ Patients ASCO 2024 TiP Poster

June 2024

TakeAim Leukemia Predictive Biomarkers ASCO 2024

April 2024

TakeAim Leukemia Emavusertib as Add-On to Venetoclax and Azacitidine in MRD+ Patients AACR 2024 TiP Poster

December 2023

TakeAim Leukemia Clinical Outcomes ASH 2023 Poster

November 2023

TakeAim Leukemia Transcriptome Analysis SITC 2023 Poster

September 2023

IRAK4 Symposium 2023 Highlights

July 2023

Emavusertib in Leukemia and Lymphoma DAVA Oncology Summit on Heme Malignancies 2023

December 2022

TakeAim Leukemia Clinical Outcomes ASH 2022 Poster

December 2022

TakeAim Leukemia Clinical Outcomes ASH 2022 Webcast Presentation

October 2022

IRAK4 Symposium 2022 Highlights

June 2022

Preclinical Emavusertib Biomarkers in AML Samples EHA 2022 Poster

June 2022

TakeAim Leukemia Clinical Outcomes EHA 2022 Oral Presentation

June 2022

TakeAim Lymphoma PCNSL Clinical and Preclinical Data EHA 2022 Poster

June 2022

TakeAim Leukemia Clinical Outcomes ASCO 2022 Poster

June 2022

TakeAim Leukemia Clinical Outcomes ASCO 2022 Poster Slide Presentation

November 2021

TakeAim Leukemia and Preclinical Data Whistler 2021 Oral Presentation

June 2021

AML and MDS Key Opinion Leader Event June 2021

June 2021

Preclinical Emavusertib + Azacitidine + Venetoclax in AML Models EHA 2021 Poster

June 2021

TakeAim Leukemia and Preclinical Data EHA 2021 Oral Presentation

December 2020

Emavusertib KOL Event ASH 2020

December 2020

TakeAim Leukemia Clinical Outcomes ASH 2020 TiP Poster

December 2019

Preclinical Spliceosome Mutation Activation of IRAK4 in MDS and AML ASH 2019 Poster

June 2019

Preclinical Emavusertib in FLT3-WT and FLT3m AML models EHA 2019 Poster

April 2019

Emavusertib Development and PK WRRS 2019 Oral Presentation

May 2016

Preclinical Emavusertib Activity, PD/PK, and Toxicity AACR 2016 Poster

1